Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
Thomas GaillardJeanne PikettyJean-Guillaume FeronNoemie GirardLea PaulyElodie GauroyLauren DarriguesBeatriz GrandalJean-Yves PiergaAnne-Sophie Hamy-PetitFabien ReyalEnora LaasPublished in: British journal of cancer (2024)
The MonarchE trial may significantly affect surgical practices due to the need for invasive procedures to identify high-risk patients for adjuvant abemaciclib treatment. The prospect of unnecessary morbidity demands less invasive N2 status determination methods. Surgical decisions must consider patient health and potential treatment benefits.
Keyphrases
- healthcare
- end stage renal disease
- study protocol
- public health
- ejection fraction
- chronic kidney disease
- randomized controlled trial
- primary care
- newly diagnosed
- early stage
- lymph node
- phase ii
- case report
- risk assessment
- climate change
- neoadjuvant chemotherapy
- mass spectrometry
- high resolution
- combination therapy
- patient reported outcomes
- social media
- molecularly imprinted
- rectal cancer
- liquid chromatography
- simultaneous determination
- solid phase extraction